Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone versus dexamethasone with abiraterone in metastatic castration-resistant prostate cancer
ChiCTR1800017327Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of abiraterone, prednisone and dexamethasone in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Recurrence-free survival. Started Aug 2018; status: recruiting.
02
Drugs
abirateroneprednisonedexamethasone
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR1800017327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017327.